Myriad
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
Illumina to Incorporate Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Premium
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater recognition of such variants.
Myriad Genetics Stock Tanks After UnitedHealthcare Pulls Coverage of PGx Panels
The payor had been covering Myriad's GeneSight assay since 2019 but has decided there is not enough evidence showing this type of test is medically necessary.
Myriad Genetics, Flatiron Health Partner on EMR Integration of MyRisk Hereditary Cancer Test
The deal will allow doctors using Flatiron's cloud-based OncoEMR electronic medical record system to order Myriad's comprehensive cancer predisposition test.
Oct 9, 2023